My Cart

Human CXCR3 Full Length Protein (VLP)

Customer Reviews
Cat. No. / Size
Price
Qty
CX3-H52P4-20ug
$620.00
CX3-H52P4-100ug
$1235.00
CX3-H52P4-500ug (250ug X 2)
$4305.00
ETA of in-stock products:2 business days
Sub-Total$ 0

Product Details

  • Synonym

    CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R, Mig-R, MigR

  • Source

    Human CXCR3 Full Length Protein-VLP (CX3-H52P4) is expressed from human 293 cells (HEK293). It contains AA Val 2 - Leu 368 (Accession # P49682-1).

    Predicted N-terminus: Asp

  • Molecular Characterization

    Virus-like particles(VLPs) are formed by self-assembly of capsid proteins from viruses. Membrane Proteins can be constituted in-situ with VLPs produced from HEK293 cell cultures. These VLPs concentrate conformationally intact membrane proteins directly on the cell surface and produce soluble, high-concentration proteins perfect for immunization and antibody screening.

    The VLPs provide the display of properly folded membrane proteins in their native cellular membrane in a compact size of 100~300 nm diameter (similar to the size of most viruses) making it optimal targets for dendritic cells in vivo and surface attachment for phage display.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SEC-HPLC.

  • Formulation

    The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

    Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • Storage

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 12 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process
  • *The isotype control of empty/mock VLP (Cat. No. VLP-N5213) is sold separately and not included in protein, you can follow this link for product information.

Customers Also Viewed

Performance Data

  • SEC-HPLC

    CXCR3 SEC-HPLC

    The purity of Human CXCR3 Full Length Protein-VLP (Cat. No. CX3-H52P4) was greater than 95% as determined by SEC-HPLC.

  • Bioactivity-ELISA

     CXCR3 ELISA

    Immobilized Human CXCR3 Full Length Protein-VLP (Cat. No. CX3-H52P4) at 5 μg/mL (100 μL/well) can bind Anti-CXCR3 Antibody, Human IgG1 with a linear range of 0.8-6 ng/mL (QC tested).

    Protocol
  • Bioactivity-SPR

     CXCR3 SPR

    Anti-CXCR3 antibody immobilized on CM5 Chip can bind Human CXCR3 Full Length Protein-VLP (Cat. No. CX3-H52P4) with an affinity constant of 60.9 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  • Identity-DLS

     CXCR3 DLS

    The mean peak Radius of VLP is 60-80 nm with more than 95% intensity as determined by dynamic light scattering (DLS).

Customer Reviews
Writing Reviews

Background

Chemokines are proteins which induce chemotaxis, promote differentiation of immune cells, and cause tissue extravasation. Given these properties, their role in anti-tumor immune response in the cancer environment is of great interest. Although immunotherapy has shown clinical benefit for some cancer patients, other patients do not respond. One of the mechanisms of resistance to checkpoint inhibitors may be chemokine signaling. The CXCL9, -10, -11/CXCR3 axis regulates immune cell migration, differentiation, and activation, leading to tumor suppression (paracrine axis). However, there are some reports that show involvements of this axis in tumor growth and metastasis (autocrine axis). Thus, a better understanding of CXCL9, -10, -11/CXCR3 axis is necessary to develop effective cancer control.

Recent Advances

 
Drug Development Progress
  • English Name:

    C-X-C motif chemokine receptor 3

  • Category:

  • Approved Drugs:

    0 Details

  • Drugs in Clinical Trials:

    2 Details

  • Highest Development Stage:

    Phase 1 Clinical

Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland